eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
P/B ratio for eFFECTOR Therapeutics, Inc. (EFTR)
P/B ratio as of 2023: -4.41
According to eFFECTOR Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -4.41. At the end of 2022 the company had a P/B ratio of 4.52.
P/B ratio history for eFFECTOR Therapeutics, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -4.41 |
| 2022 | 4.52 |
| 2021 | 19.35 |
| 2020 | -1.13 |
| 2019 | -9.93 |